Potential Treatment to Prevent Organ Inflammation

Metablok (LSALT peptide) is our lead drug candidate for treating inflammation in the lungs, liver and kidneys. 

Arch believes Metablok has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role. In August 2019, a scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins published a paper in the journal Cell  describing a novel mechanism of action for organ inflammation. In the publication, the enzyme...

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

• Government of Canada contribution up to $6.7 Million

• Funding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of Canada’s Plan to Mobilize Science to fight...

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver


Saurav Roy Choudhury, Liane Babes, Jennifer J. Rahn, Bo-Young Ahn, Kimberly-Ann R. Goring, Jennifer C. King, Arthur Lau, Björn Petri, Xiaoguang Hao, Andrew K. Chojnacki, Ajitha Thanabalasuriar, Erin F. McAvoy, Sébastien Tabariès, Christoph...

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is currently a Professor at the University of Calgary in the Departments of Oncology and Biochemistry & Molecular Biology. He is a former Canada Research Chair in Cancer...

    Bridging the gap between science and business

    Bringing new medical innovation to market.

    Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual...

    News &

    Unaware of Any Undisclosed Material Change

    TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ...

    Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

    TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates...

    Stock information

    Arch Biopartners trades as ARCH:TSXV in Canada, and ACHFF:OTCBB in the United States.

    Management and Board of Directors

    Investor Relations and Investor Information